Home › Funds › Kohlberg Kravis Roberts & Co. L.P. › ARWR
Kohlberg Kravis Roberts & Co. L.P. position in ARWR
ARROWHEAD PHARMACEUTICALS IN · Health Care
Kohlberg Kravis Roberts & Co. L.P. reported holding 800,000 shares of ARWR (ARROWHEAD PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$958K, representing 0.02% of its reported portfolio and ranking #32 among its reported holdings. Kohlberg Kravis Roberts & Co. L.P. has disclosed ARWR holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Kohlberg Kravis Roberts & Co. L.P.'s ARWR position evolved
Kohlberg Kravis Roberts & Co. L.P. first disclosed a stake in ARWR in Q1 2026 at 800,000 shares (US$830K). The position peaked in Q2 2026 at 800,000 shares, worth US$958K. Across 2 filings, Kohlberg Kravis Roberts & Co. L.P. held the position steady without any share-count change. The most recent filing (Q2 2026) shows 800,000 shares valued at US$958K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 800.00K | $829.68K | New |
| Q2 2026 | 800.00K | $957.96K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ARWR and 13F data
ARWR (ARROWHEAD PHARMACEUTICALS IN) is a Health Care company. 53 other funds we track also report a position in ARWR — the largest reported positions include Avoro Capital Advisors LLC (US$925.6M), FRED ALGER MANAGEMENT, LLC (US$269.1M), BAKER BROS. ADVISORS LP (US$162.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ARWR
- Avoro Capital Advisors LLC 11.36M sh · $925.59M · Q2 2026
- FRED ALGER MANAGEMENT, LLC 3.30M sh · $269.14M · Q2 2026
- BAKER BROS. ADVISORS LP 1.99M sh · $162.43M · Q2 2026
- Siren, L.L.C. 1.72M sh · $139.83M · Q2 2026
- Vestal Point Capital, LP 1.57M sh · $128.38M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.39M sh · $113.22M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 1.35M sh · $110.08M · Q2 2026
- Hood River Capital Management LLC 1.12M sh · $91.35M · Q2 2026
- SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 830.25K sh · $67.67M · Q2 2026
- Western Financial Corp/CA 820.24K sh · $53.68M · Q3 2026
- READYSTATE ASSET MANAGEMENT LP 25.00M sh · $29.94M · Q2 2026
- MACKAY SHIELDS LLC 27.19M sh · $27.84M · Q3 2026
More on Kohlberg Kravis Roberts & Co. L.P.
FAQ
How long has Kohlberg Kravis Roberts & Co. L.P. held ARWR?
Kohlberg Kravis Roberts & Co. L.P. has disclosed ARWR holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Kohlberg Kravis Roberts & Co. L.P.'s current position in ARWR?
As of Q2 2026, Kohlberg Kravis Roberts & Co. L.P. holds 800.00K shares of ARWR (ARROWHEAD PHARMACEUTICALS IN), valued at $957.96K, representing 0.02% of its reported portfolio and ranking #32.
Has Kohlberg Kravis Roberts & Co. L.P. been buying or selling ARWR?
In the latest 13F filing (Q2 2026), Kohlberg Kravis Roberts & Co. L.P. held unchanged its position in ARWR. The position peaked in Q2 2026 at 800.00K shares.
Which other funds hold ARWR?
Other major institutional holders of ARWR include Avoro Capital Advisors LLC, FRED ALGER MANAGEMENT, LLC, BAKER BROS. ADVISORS LP, among 53 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.